Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THX-110 in Tourette Syndrome
NCT03651726Phase 2Unknown
- Sponsor
- SciSparc
- Start
- Aug 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Tourette syndrome (TS) comparing THX-110 with Placebo (2 arms). Primary endpoint: Change in Yale Global Tic Severity Scale Total Tic Score at 12 weeks. Status: unknown.
02
Drugs
dronabinol + palmitoylethanolamide
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT03651726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651726.